A January 2026 Complete Response Letter from the FDA — triggered not by clinical inadequacy but by questions about analytical methods used in production batch testing — delayed leniolisib’s expansion into the 4-to-11 age band for roughly nine months. That gap matters because the Phase III data supporting the resubmission were already solid: across 12 weeks of open-label treatment, children showed reduced lymphadenopathy and increased naïve B cells at every dose level tested, with all treatment-emergent adverse events graded mild to moderate and zero drug-related serious adverse events. The science was never the problem. The manufacturing documentation was.
Pharming resolved the deficiency through a Type A meeting with the FDA on March 26, 2026, submitted the additional analytical data, and now has a PDUFA target action date of October 24, 2026. The current sNDA covers 40 mg and 50 mg twice-daily dosing for patients weighing 27 kg or more — a meaningful slice of the pediatric APDS population, though not the whole of it. A separate submission for lower-weight patients (under 27 kg) is planned for later this summer, meaning FDA review of that cohort will trail October’s decision by at least several months. Pharming is threading a sequential regulatory needle rather than resolving pediatric access in one stroke.
The clinical logic for this age extension is coherent. Leniolisib received U.S. approval in March 2023 for patients 12 and older with APDS, a rare primary immunodeficiency caused by gain-of-function variants in PIK3CD or PIK3R1 that hyperactivate the PI3Kδ pathway. APDS carries a reported median seven-year diagnostic delay, and because the disease is progressive, that delay compounds — driving permanent lung damage and elevated lymphoma risk before many patients are ever correctly identified. Treating at age 4 rather than 12 is not a market expansion maneuver; it is an attempt to interrupt pathology before it accumulates. Japan already approved leniolisib for patients 4 and older in March 2026, giving Pharming a regulatory precedent it can point to even if the FDA review proceeds on its own terms.
The single number to track now is the lower-weight submission timeline. If Pharming files for sub-27 kg patients before September 2026 as implied, the FDA could theoretically act on both cohorts in close sequence — but a delayed filing pushes full pediatric coverage into 2027. Enrollment completion on NCT05438407 and whether Pharming discloses the sub-27 kg data package on schedule will signal whether that compressed pediatric arc holds or fractures.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
